|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Overexpression of FMO5 was associated with an advanced clinical stage of cancer (P=0.018) and lymph node metastasis (P=0.03).
|
29456741 |
2018 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The FMO5 protein level in colon cancer tissues was significantly higher than that in normal colon tissues (P<0.001).
|
29456741 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier survival curves showed that higher FMO5 mRNA indicated a shorter overall survival in patients with CRC compared with a low expression of FMO5 (P=0.029).
|
29456741 |
2018 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The TCGA dataset also demonstrated that FMO5 was upregulated in CRC with advanced clinical stage (P=0.047), lymph node metastasis (P=0.045) and distant metastasis (P=0.030).
|
29456741 |
2018 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
A high expression of FMO5 may serve roles in colorectal carcinogenesis and distant metastasis.
|
29456741 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The TCGA dataset also demonstrated that FMO5 was upregulated in CRC with advanced clinical stage (P=0.047), lymph node metastasis (P=0.045) and distant metastasis (P=0.030).
|
29456741 |
2018 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The FMO5 protein level in colon cancer tissues was significantly higher than that in normal colon tissues (P<0.001).
|
29456741 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Overexpression of FMO5 was associated with an advanced clinical stage of cancer (P=0.018) and lymph node metastasis (P=0.03).
|
29456741 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of flavin-containing monooxygenase 5 predicts poor prognosis in patients with colorectal cancer.
|
29456741 |
2018 |
|
Mental disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Our study provides evidence that the same genes (e.g., MC4R, FIBIN, and FMO5) harbor both common and rare variants affecting body size and that anthropometric traits share genetic loci with developmental and psychiatric disorders.Individual SNPs have small effects on anthropometric traits, yet the impact of CNVs has remained largely unknown.
|
28963451 |
2017 |
|
Abnormal behavior
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Our study provides evidence that the same genes (e.g., MC4R, FIBIN, and FMO5) harbor both common and rare variants affecting body size and that anthropometric traits share genetic loci with developmental and psychiatric disorders.Individual SNPs have small effects on anthropometric traits, yet the impact of CNVs has remained largely unknown.
|
28963451 |
2017 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP2A6, CYP2B6, FMO5 and NAT1 emerged as new putative ERalpha-responsive genes in human breast cancer.
|
15084249 |
2004 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Relapse-free survival was longer among patients with FMO5-overexpressing tumors or NAT1-overexpressing tumors (P = 0.0066 and P = 0.000052, respectively), but only NAT1 status retained prognostic significance in Cox multivariate regression analysis (P = 0.0013).
|
15084249 |
2004 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP2A6, CYP2B6, FMO5 and NAT1 emerged as new putative ERalpha-responsive genes in human breast cancer.
|
15084249 |
2004 |